狄诺塞麦治疗骨转移的效果如何？

It is a new drug launched in my country in May 2019 that can reduce the risk of fractures in cancer patients. With the continuous deepening of research on denosumab, denosumab has brought good news to more and more patients in the treatment of bone-related fields.

The effect of denosumab in the treatment of bone metastases is of great concern to everyone. The Medical Companion Brigade has collected and compiled some relevant trials, hoping to be helpful to you.

A randomized, placebo-controlled Phase III clinical trial called DEFEND (Denosumab Fortifies Bone Density) evaluated the role of denosumab in preventing osteoporosis in postmenopausal women. The average age of the patients included in this trial was 59.4 years old, and their spinal T-scores ranged from -1.0 to -2.5 (mean value -1.61). They were divided into denosumab treatment group (n=166) and placebo group (n=166). Among them, the treatment group was treated by subcutaneous injection of 60 mg once every 6 months. Both groups of patients were supplemented with 1,000 mg of vegetarian calcium every day, and the level of plasma 25-hydroxyvitamin D was used to determine whether vitamin D supplementation was needed. The primary outcome measure was the change from baseline in vertebral BMD measured by dual-energy X-ray absorptiometry (DXA).

The results showed that after 24 months, denosumab significantly increased the BMD value of the spine by 6.5%, while it was reduced by 0.6% in the placebo group. The effect of denosumab was significantly better than that of the placebo group. Not only that, the BMD values ​​of denosumab increased significantly in all tested sites such as the hip bone and distal radius. At the same time, markers of bone resorption and formation were significantly reduced. The overall incidence of adverse reactions in the treatment group was similar to that in the placebo group during the observation period.

In general, it can effectively prevent the occurrence of osteoporosis and has a positive therapeutic effect on bone metastasis. At the same time, it is also relatively safe and is a good choice for patients.